argenx SE (ARGX)

Market Cap	26.26B
Revenue (ttm)	10.74M
Net Income (ttm)	-436.15M
Shares Out	59.08M
EPS (ttm)	-7.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,335
Open	443.65
Previous Close	445.34
Day's Range	441.71 - 445.02
52-Week Range	333.07 - 550.76
Beta	0.54
Analysts	Strong Buy
Price Target	533.22 (+20.13%)
Earnings Date	Oct 31, 2023

About ARGX

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 18, 2017
• Employees: 843
• Stock Exchange: NASDAQ
• Ticker Symbol: ARGX

Financial Performance

In 2022, argenx SE's revenue was 10.03 million, a decrease of -97.98% compared to the previous year's 497.28 million. Losses were -709.59 million, 73.8% more than in 2021.

Financial numbers in EUR

Analyst Forecast

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $533.22, which is an increase of 20.13% from the latest price.

Price Target

$533.22

(20.13% upside)

Analyst Consensus: Strong Buy